Regeneron Pharmaceuticals, Inc. (REGN) Q1 2013 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Up 7.05%

Regeneron's strong EPS performance, significantly above expectations, contributed to a 7.05% increase in stock price. The positive surprise indicates effective cost management and operational efficiency. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.78	N/A	+68.56%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Confident

Management expressed confidence in their financial performance, particularly in EPS. They emphasized their commitment to pipeline development.

We are pleased with our EPS performance this quarter.

Our focus remains on advancing our pipeline.

Regeneron Pharmaceuticals Beats on EPS, Stock Up 7.05%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Up 7.05%

Key numbers

Management commentary